Literature DB >> 29434997

Function of Axl receptor tyrosine kinase in non-small cell lung cancer.

Guoan Zhang1, Meng Wang2, Hongli Zhao3, Wen Cui1.   

Abstract

Axl receptor tyrosine kinase (hereafter Axl) is a member of the tyrosine-protein kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein kinase Mer family of receptor tyrosine kinases, possessing multiple different functions in normal cells. Axl is overexpressed and activated in numerous different human cancer types, triggering several signaling pathways and enhancing tumor progression. The present review assesses previous studies on the function of Axl in non-small cell lung cancer (NSCLC). Axl is overexpressed in the tumor tissues of a number of patients with NSCLC and is associated with poorer clinical outcomes; it promotes NSCLC tumor growth, invasion/metastasis, drug resistance and the epithelial-mesenchymal transition, thus providing a survival advantage to tumor cells. Therefore, Axl may be a promising target in NSCLC treatment.

Entities:  

Keywords:  Axl receptor tyrosine kinase; drug resistance; epithelial-mesenchymal transition; invasion; metastasis; non-small cell lung cancer

Year:  2017        PMID: 29434997      PMCID: PMC5778882          DOI: 10.3892/ol.2017.7694

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  89 in total

1.  Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells.

Authors:  A M Healy; J J Schwartz; X Zhu; B E Herrick; B Varnum; H W Farber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-06       Impact factor: 5.464

Review 2.  Immunobiology of the TAM receptors.

Authors:  Greg Lemke; Carla V Rothlin
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

3.  Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients.

Authors:  Ju Han; Rui Tian; Bicheng Yong; Canqiao Luo; Pingxian Tan; Jingnan Shen; Tingsheng Peng
Journal:  Biochem Biophys Res Commun       Date:  2013-05-15       Impact factor: 3.575

Review 4.  Axl kinase as a key target for oncology: focus on small molecule inhibitors.

Authors:  Clémence Feneyrolles; Aurélia Spenlinhauer; Léa Guiet; Bénédicte Fauvel; Bénédicte Daydé-Cazals; Pierre Warnault; Gwénaël Chevé; Aziz Yasri
Journal:  Mol Cancer Ther       Date:  2014-08-19       Impact factor: 6.261

Review 5.  Cell signaling by receptor tyrosine kinases.

Authors:  Mark A Lemmon; Joseph Schlessinger
Journal:  Cell       Date:  2010-06-25       Impact factor: 41.582

6.  Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.

Authors:  A Angelillo-Scherrer; P de Frutos; C Aparicio; E Melis; P Savi; F Lupu; J Arnout; M Dewerchin; M Hoylaerts; J Herbert; D Collen; B Dahlbäck; P Carmeliet
Journal:  Nat Med       Date:  2001-02       Impact factor: 53.440

7.  Activation of AXL and antitumor effects of a monoclonal antibody to AXL in lung adenocarcinoma.

Authors:  Shinya Iida; Yasuhiro Miki; Takashi Suzuki; Kazushige Mori; Mikiyoshi Saito; Hiromichi Niikawa; Takashi Kondo; Hisafumi Yamada-Okabe; Hironobu Sasano
Journal:  Anticancer Res       Date:  2014-04       Impact factor: 2.480

8.  Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.

Authors:  Patrick Reichl; Meng Fang; Patrick Starlinger; Katharina Staufer; Rudolf Nenutil; Petr Muller; Kristina Greplova; Dalibor Valik; Steven Dooley; Christine Brostjan; Thomas Gruenberger; Jiayun Shen; Kwan Man; Michael Trauner; Jun Yu; Chun Fang Gao; Wolfgang Mikulits
Journal:  Int J Cancer       Date:  2015-01-13       Impact factor: 7.396

9.  Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.

Authors:  Song Yi Bae; Ji-Young Hong; Hye-Jung Lee; Hyen Joo Park; Sang Kook Lee
Journal:  Oncotarget       Date:  2015-04-30

10.  Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.

Authors:  Kari R Fischer; Anna Durrans; Sharrell Lee; Jianting Sheng; Fuhai Li; Stephen T C Wong; Hyejin Choi; Tina El Rayes; Seongho Ryu; Juliane Troeger; Robert F Schwabe; Linda T Vahdat; Nasser K Altorki; Vivek Mittal; Dingcheng Gao
Journal:  Nature       Date:  2015-11-11       Impact factor: 49.962

View more
  15 in total

1.  Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.

Authors:  Louise A Koopman; Mikkel G Terp; Gijs G Zom; Maarten L Janmaat; Kirstine Jacobsen; Elke Gresnigt-van den Heuvel; Marcel Brandhorst; Ulf Forssmann; Freddy de Bree; Nora Pencheva; Andreas Lingnau; Maria A Zipeto; Paul Whi Parren; Esther Cw Breij; Henrik J Ditzel
Journal:  JCI Insight       Date:  2019-11-01

2.  Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Authors:  Amita Patnaik; Shirish Gadgeel; Kyriakos P Papadopoulos; Drew W Rasco; Naomi B Haas; Hirak Der-Torossian; Demiana Faltaos; Diane Potvin; Vanessa Tassell; Manal Tawashi; Richard Chao; Peter J O'Dwyer
Journal:  Target Oncol       Date:  2022-03-28       Impact factor: 4.864

3.  Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration.

Authors:  Anurima Majumder; Sina Hosseinian; Mia Stroud; Emma Adhikari; James J Saller; Matthew A Smith; Guolin Zhang; Shruti Agarwal; Marc Creixell; Benjamin S Meyer; Fumi Kinose; Kiah Bowers; Bin Fang; Paul A Stewart; Eric A Welsh; Theresa A Boyle; Aaron S Meyer; John M Koomen; Eric B Haura
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 6.333

Review 4.  RNA-based therapies: A cog in the wheel of lung cancer defense.

Authors:  Parvez Khan; Jawed Akhtar Siddiqui; Imayavaramban Lakshmanan; Apar Kishor Ganti; Ravi Salgia; Maneesh Jain; Surinder Kumar Batra; Mohd Wasim Nasser
Journal:  Mol Cancer       Date:  2021-03-19       Impact factor: 27.401

Review 5.  The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview.

Authors:  Martha Wium; Juliano D Paccez; Luiz F Zerbini
Journal:  Cells       Date:  2018-10-12       Impact factor: 6.600

Review 6.  [Advances in the Study of Tumor-associated Macrophages in Lung Cancer].

Authors:  Yanyan Qiao; Enqing Fu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2022-01-20

7.  SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.

Authors:  Chun-Bong Synn; Sung Eun Kim; Hee Kyu Lee; Min-Hwan Kim; Jae Hwan Kim; Ji Min Lee; Ha Ni Jo; Wongeun Lee; Dong Kwon Kim; Youngseon Byeon; Young Seob Kim; Mi Ran Yun; Chae-Won Park; Jiyeon Yun; Sangbin Lim; Seong Gu Heo; San-Duk Yang; Eun Ji Lee; Seul Lee; Hunmi Choi; You Won Lee; Jae Seok Cho; Do Hee Kim; Sungho Park; Jung-Ho Kim; Yewon Choi; Sung Sook Lee; Beung-Chul Ahn; Chang Gon Kim; Sun Min Lim; Min Hee Hong; Hye Ryun Kim; Kyoung-Ho Pyo; Byoung Chul Cho
Journal:  Clin Transl Immunology       Date:  2021-12-29

Review 8.  Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Justin A Chen; Jonathan W Riess
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

9.  Pharmaceutical inhibition of AXL suppresses tumor growth and invasion of esophageal squamous cell carcinoma.

Authors:  Sha Han; Yequan Wang; Chengyan Ge; Mingtao Gao; Xintong Wang; Feiyu Wang; Lei Sun; Sheng Li; Tingting Dong; Zhen Dang; Wen Cui; Guoan Zhang; Ning Liu
Journal:  Exp Ther Med       Date:  2020-09-02       Impact factor: 2.447

Review 10.  The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.

Authors:  Martha Wium; Aderonke F Ajayi-Smith; Juliano D Paccez; Luiz F Zerbini
Journal:  Cancers (Basel)       Date:  2021-03-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.